Linear energy transfer optimization in proton therapy of sinonasal cancer
- Journal
- Physics and imaging in radiation oncology (Q1)
- Published
- 7 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Miriam Paetzel, Camilla H Stokkevåg, Camilla G Boer, Jon Espen Dale, Andreas H Handeland, Kristian S Ytre-Hauge, et al.
- PMID
- 43060556
- DOI
- 10.1016/j.phro.2026.101122
Why clinicians should know about it
- Picked for Medical Physics (top studies of the week, 22 November 2026): EPID-based VMAT audit framework with multi-institutional validation
Abstract
BACKGROUND: Variations in relative biological effectiveness (RBE) and linear energy transfer (LET) in proton therapy may contribute to unexpected side effects in organs of interest (OOIs). This study assessed the feasibility of LET optimization in intensity-modulated proton therapy (IMPT) for sinonasal cancer, aiming to reduce dose-averaged LET (LETd). MATERIALS AND METHODS: Robust optimized IMPT reference plans (Ref) were created for 16 patients (clinical target volume (CTV) doses: 64-70 Gy[RBE1.1]) assuming a fixed RBE = 1.1, 2 mm setup and 3.5% range uncertainties. LET optimized plans (LETopt) were generated from Ref plans using identical dose guidance, with additional LETd objectives (LETd < 3 keV/μm at ≥30 Gy[RBE1.1]) to the brainstem, chiasm and optic nerves. Plans were compared in terms of CTV coverage, OOI dose (RBE1.1), mean LETd (LETdmean) and variable RBE-weighted doses (RBEVAR). RESULTS: All Ref and LETopt plans met the CTV dose criteria. The median LETdmean across the patients was reduced in the chiasm (3.1 vs 2.3 keV/μm, P = 0.009), right optic nerve (3.1 vs 2.5 keV/μm, P = 0.016), and left optic nerve (2.7 vs 2.7 keV/μm, P = 0.023). RBEVAR doses (D0.03cm3) to OOIs were also significantly decreased, achieving patient-specific reductions from >56 Gy (RBEVAR) to below the 54 Gy (RBEVAR) threshold in the brainstem, chiasm, and optic nerves. CONCLUSIONS: LET optimization significantly reduced LETdmean and RBEVAR doses to critical OOIs without compromising CTV coverage. However, its effectiveness was patient specific, with notable variability in RBEVAR D0.03cm3 doses across models, underscoring the need for individualized assessment.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.